NCT06015932 Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients
| NCT ID | NCT06015932 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Hematopoietic and Lymphoid System Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2017-12-20 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2017-12-20 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial tests how well cognitive behavioral cancer stress management (CBCSM) group sessions work to decrease psychological distress in cancer patients. CBCSM teaches patients how to recognize and reduce the impacts of cancer associated stress on the biological, psychological, and social life domains.
Eligibility Criteria
Inclusion Criteria: * Eligible for the cognitive behavioral cancer stress management (CBCSM) clinical service * Cancer diagnosis with predicted survival \> 1 year * Cancer treatment within past 1 year or treatment planning in progress * Age \>= 18-years * Moderate distress screen, indicated by Impact of Event Scale-Revised (IES-R) score \>= 14 or clinical judgment * Written informed research consent Exclusion Criteria: * Inability to actively participate in and learn from group therapy (e.g., psychotic symptoms, neurological condition, personality pathology) as determined by clinical judgment in clinical consultation (Individual therapy or alternative group therapy will be offered)
Contact & Investigator
Shawna L. Ehlers, Ph.D., L.P.
PRINCIPAL INVESTIGATOR
Mayo Clinic in Rochester
Frequently Asked Questions
Who can join the NCT06015932 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematopoietic and Lymphoid System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06015932 currently recruiting?
Yes, NCT06015932 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.
Where is the NCT06015932 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06015932 clinical trial?
NCT06015932 is sponsored by Mayo Clinic. The principal investigator is Shawna L. Ehlers, Ph.D., L.P. at Mayo Clinic in Rochester. The trial plans to enroll 400 participants.